鹽野義完成 RADICAVA 藥物權利收購
Shionogi Completes Acquisition of Drug Rights for RADICAVA
2026年4月1日，製藥公司鹽野義製藥完成了一項重大交易，以25億美元從田邊三菱製藥收購了肌萎縮性脊髓側索硬化症治療藥物RADICAVA的全球權利。
On April 1, 2026, the pharmaceutical company Shionogi & Co., Ltd. finalized a major deal, acquiring the global rights to the ALS treatment RADICAVA from Tanabe Pharma Corporation for $2.5 billion.
這一策略性舉措標誌著鹽野義製藥在尋求擴大其罕見疾病市場版圖時的重要轉向。
This strategic move marks a significant pivot for Shionogi as it seeks to expand its footprint in the rare disease market.
RADICAVA（通用名為依達拉奉）是治療肌萎縮性脊髓側索硬化症這一漸進性神經退化性疾病患者的關鍵療法。
RADICAVA, known by the generic name edaravone, is a vital therapy for patients living with Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative condition.
透過將該藥物的靜脈注射劑型與口服懸浮液劑型整合至其產品組合中，鹽野義製藥獲得了一個成熟的商業平台以及一個由100多名專業人員組成的專責團隊。
By integrating both the intravenous and oral suspension versions of the drug into its portfolio, Shionogi gains an established commercial platform and a dedicated team of over 100 professionals.
此項收購預計將使鹽野義製藥的年銷售額增加約7億美元，同時協助該公司開發針對其他罕見疾病（如龐貝氏症）的未來治療方法。
This acquisition is expected to bolster Shionogi’s annual sales by approximately $700 million while helping them develop future treatments for other rare conditions like Pompe disease.
對於患者群體而言，這次過渡確保了照護的延續性，因為鹽野義製藥將優先維護現有的支持服務。
For the patient community, the transition ensures continuity of care, as Shionogi prioritizes maintaining existing support services.
這筆交易凸顯了日本製藥產業的廣泛趨勢，即各公司正日益將業務模式重新聚焦於專業化、高影響力的治療領域，以解決尚未被滿足的重大醫療需求。
This deal highlights a broader trend within the Japanese pharmaceutical industry, where companies are increasingly refocusing their business models on specialized high-impact therapeutic areas to address significant unmet medical needs.
